CAS 2209085-22-1

N-[(1S,3aS,3bR,5aS,7S,9aS,9bS,11aS)-1-(isoquinolin-7-yl)-9a,11a-dimethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-7-yl]-1-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}-N

CAS: 2209085-22-1

N-[(1S,3aS,3bR,5aS,7S,9aS,9bS,11aS)-1-(isoquinolin-7-yl)-9a,11a-dimethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-7-yl]-1-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}-N

Formula: C₅₃H₆₉N₅O₉

Purezza: 99.82%

Peso molecolare: 920.14

Ref: 54-OR1120058

JH-XI-10-02

CAS: 2209085-22-1

JH-XI-10-02 selectively degrades CDK8 (IC50: 159 nM) through proteasome, sparing CDK8 mRNA and CDK19.

Formula: C₅₃H₆₉N₅O₉

Purezza: 98%

Colore e forma: Solid

Peso molecolare: 920.161

Ref: TM-T13743

Jh-xi-10-02

CAS: 2209085-22-1

Jh-xi-10-02 is a heterobifunctional molecule that inhibits ubiquitin ligases and targets cancer cells. It is an inhibitor of the ubiquitin-proteasome pathway, which is a cellular pathway that degrades and recycles proteins. Jh-xi-10-02 prevents the degradation of cortistatin, leading to increased levels of this protein in mammalian cells. This drug also has pharmacokinetic properties and can be synthesized without toxicities. Jh-xi-10-02 has been shown to inhibit the growth of cancer cells in culture and in animal models, suggesting it may be a potential anticancer agent.

Formula: C₅₃H₆₉N₅O₉

Purezza: Min. 95%

Peso molecolare: 920.14 g/mol

Ref: 3D-JND08522